Kaitong Zhao, Jiarui Bai, Guojian Zhang. Clinical application value and research progress of 90Y microspheres in the treatment of hepatocellular cancinoma[J]. Int J Radiat Med Nucl Med, 2023, 47(7): 435-438. DOI: 10.3760/cma.j.cn121381-202209022-00321
Citation: Kaitong Zhao, Jiarui Bai, Guojian Zhang. Clinical application value and research progress of 90Y microspheres in the treatment of hepatocellular cancinoma[J]. Int J Radiat Med Nucl Med, 2023, 47(7): 435-438. DOI: 10.3760/cma.j.cn121381-202209022-00321

Clinical application value and research progress of 90Y microspheres in the treatment of hepatocellular cancinoma

  • Liver cancer can be divided into two categories: primary liver cancer and secondary liver cancer. Hepatocellular cancinoma (HCC) is the most common type of primary liver cancer, which has the characteristics of high incidence and high mortality. 90Y microsphere selective internal radiotherapy (SIRT) can be used in many stages of liver cancer, which can reduce the tumor, increase the volume of the remaining liver, treat portal vein tumor thrombus and improve the quality of life for patients. The clinical application value and research progress of 90Y microspheres SIRT in the treatment of HCC was introduced.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return